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Abstract
Background: Antimicrobial resistance is an under-appreciated threat to public health in nations around the
globe. With globalization booming, it is important to understand international patterns of resistance. If countries
already experience similar patterns of resistance, it may be too late to worry about international spread. If large
countries or groups of countries that are likely to leap ahead in their integration with the rest of the world –
China being the standout case – have high and distinctive patterns of resistance, then a coordinated response
could substantially help to control the spread of resistance. The literature to date provides only limited evidence
on these issues.
Methods: We study the recent patterns of antibiotic resistance in three geographically separated, and culturally
and economically distinct countries – China, Kuwait and the United States – to gauge the range and depth of this
global health threat, and its potential for growth as globalization expands. Our primary measures are the
prevalence of resistance of specific bacteria to specific antibiotics. We also propose and illustrate methods for
aggregating specific "bug-drug" data. We use these aggregate measures to summarize the resistance pattern for
each country and to study the extent of correlation between countries' patterns of drug resistance.
Results: We find that China has the highest level of antibiotic resistance, followed by Kuwait and the U.S. In a
study of resistance patterns of several most common bacteria in China in 1999 and 2001, the mean prevalence of
resistance among hospital-acquired infections was as high as 41% (with a range from 23% to 77%) and that among
community- acquired infections was 26% (with a range from 15% to 39%). China also has the most rapid growth
rate of resistance (22% average growth in a study spanning 1994 to 2000). Kuwait is second (17% average growth
in a period from 1999 to 2003), and the U.S. the lowest (6% from 1999 to 2002). Patterns of resistance across
the three countries are not highly correlated; the most correlated were China and Kuwait, followed by Kuwait
and the U.S., and the least correlated pair was China and the U.S.
Conclusion: Antimicrobial resistance is a serious and growing problem in all three countries. To date, there is
not strong international convergence in the countries' resistance patterns. This finding may change with the
greater international travel that will accompany globalization. Future research on the determinants of drug
resistance patterns, and their international convergence or divergence, should be a priority.
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In 1942, the first U.S. patient with streptococcal infection
was miraculously cured with a small dose of penicillin.
Sixty years later, penicillin-resistant Streptococcus is wide-
spread. Such antimicrobial resistance threatens the health
of many throughout the world, since both old and new
infectious diseases remain a formidable public health
threat.
Among the issues that merit further scrutiny for under-
standing the possible spread of antimicrobial resistance,
few are as salient as the impact of globalization. Clearly
the movement of people and goods around the globe con-
tributes to transmission of disease [1,2]. To what extent
drug resistance and globalization are similarly related
remains unclear. The breakout of Severe Acute Respiratory
Syndrome (SARS) in the spring of 2003 illustrates how an
infectious disease with limited therapeutic options can
spread rapidly across national borders. With globalization
booming, it is important to understand international pat-
terns of resistance. If countries already experience similar
patterns of resistance, it may be too late to worry about
international spread. If large countries or groups of coun-
tries that are likely to leap ahead in their integration with
the rest of the world – China being the standout case –
have high and distinctive patterns of resistance, then a
coordinated response could help substantially to control
the spread of resistance. The literature to date provides
only limited evidence on these issues.
We study the pattern of antibiotic resistance in specific
countries to gauge the range and depth of this global
health threat. China and the U.S. stand out as good
choices for study. Both are world economic powerhouses
increasingly responding to the forces of economic globali-
zation. In addition, both are major consumers of antibiot-
ics, with the U.S. also being a leading source of new
antibiotics. On the other hand, it would also be interest-
ing to compare patterns of antibiotic resistance in smaller
countries that stand relatively distant from these two.
Accordingly, we compare the experiences of the U.S. and
China with new data on the resistance experience of
Kuwait.
The first section gives brief background on antibiotic
resistance and its costs. We then turn to a detailed compar-
ison of surveillance data from China, Kuwait, and the U.S.
We conclude with a plea for more research and attention
on this critical issue for health and globalization.
Background: The challenge of antimicrobial 
resistance
According to laws of Darwinian evolution, antimicrobial
use creates a selection pressure on microorganisms: weak
ones are killed, but stronger ones might adapt and survive.
When pathogenic microorganisms can multiply beyond
some critical mass in the face of invading antimicrobials,
treatment outcome is compromised; this phenomenon is
referred as antimicrobial resistance (AMR) [3-9]. This
paper focuses on antibiotic resistance, a major form of
AMR.
Resistance mechanisms may develop over months or
years [6]. Once established, a single resistance mechanism
can often allow a bacterium to resist multiple drugs. It
remains unclear whether resistance is reversible, and thus
whether drug effectiveness is a renewable or non-renewa-
ble resource [10-15]. Drug resistance raises the cost of
treatment for infectious diseases, sometimes manifold, as
well as increasing morbidity and mortality from such dis-
eases [16-23].
The greatest long-term threat of AMR is that resistant
strains erode drug efficacy over time. The development of
drug-resistant Staphylococci aureus (SAU) well illustrates
the see-saw battle between pathogens and drugs. SAU is a
bacterium that harmlessly lives in the human body but
can cause infections on wounds or lesions. After the clini-
cal application of penicillin in the 1940s, SAU soon
adapted to the treatment mechanism of penicillin, and by
the 1950s, almost half of SAU strains had become resist-
ant to penicillin. A new antibiotic, methicillin, was devel-
oped in the 1960s. Yet by the late 1970s, methicillin-
resistant SAU, i.e. MRSA, again became widespread. Today
MRSA has become a major infectious culprit that can only
be effectively treated with vancomycin, one of the few last
killers of superbugs. Unfortunately, in 1996, a Japanese
hospital reported the first case of vancomycin-resistant
SAU (VRSA) during surgery on a four-month-old boy. The
U.S., France and Hong Kong subsequently all reported
VRSA incidents. A few years later in 2000, linezolid was
launched as a new antibiotic to combat both MRSA and
VRSA. But only one year later, Boston researchers reported
the first case of linezolid-resistant MRSA in an 85-year-old
man undergoing peritoneal dialysis. After failing to con-
tain his MRSA by linezolid, researchers tried five antibiot-
ics (ampicillin, azithromycin, gentamicin, levofloxacin,
and quinupristin-dalfopristin) but the unlucky man even-
tually died from the uncontrollable infection [24].
Resistant pathogens within a hospital or specific commu-
nity can spread to a nation at large or across national
boundaries. Thus, for example, rapidly increasing travel
and migration within China probably contributes to the
growth of that nation's resistance problem. It may also
spur the spread of China's resistance problems overseas as
globalization greatly increases travel from and to that
nation (see Figure 1).Globalization and Health 2006, 2:6 http://www.globalizationandhealth.com/content/2/1/6
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Methods
We collected data on drug resistance in China, the U.S.
and Kuwait, drawing from published studies, reports from
national surveillance systems, and previously unpub-
lished data from a large hospital in Kuwait. Such data
must be viewed with caution. Differences between coun-
tries arise not only from genuine differences in preva-
lence, but also from differences in sampling strategies,
laboratory processing, and standards for defining a "resist-
ant" strain. Moreover, within-country comparisons across
time are biased by measurement error, particularly for
small samples. However, analysis of the currently availa-
ble data does yield some evidence and may help to raise
awareness and efforts to improve the data and methods
for addressing the problem.
Our primary measure is the prevalence of resistance by a
specific bacterium to a specific drug. The prevalence is cal-
culated as the number of resistant isolates divided by the
number of total isolates collected, multiplied by 100. We
compute growth rates of resistance to specific bacteria
using standard year-on-year growth calculations. Where
appropriate, we smooth variance in small-sample data
series by using three-year running averages.
We also develop methods to aggregate specific "bug-drug"
data to summarize the resistance pattern for each country.
These measures weight resistance rates by (1) the isolation
frequency for each bacterium (that is, the proportion of a
particular bacterium among all bacteria studied); and,
where possible, by (2) the proportion of resistant cases
hospital- versus community-acquired; and (3) the fre-
quency with which each drug is used to treat infections
caused by each bacterium. (For most calculations, meas-
ure (3) is not available.) Finally, we compare and contrast
each country's resistance experience and, using the subset
of data comparable across the three countries, examine
correlations in patterns of resistance.
These methods represent preliminary steps to gauge
whether patterns of antibiotic resistance converge over
time amongst countries that currently have little popula-
Travel to and from China has increased tremendously over the past decade Figure 1
Travel to and from China has increased tremendously over the past decade.
0
20000
40000
60000
80000
100000
120000
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
0
5000
10000
15000
20000
25000
30000
35000
Thousands persons Thousands persons
Arrivals of
foreigners to China
(left axis)
Departures of Chinese
residents to overseas
(right axis)
Source: CEIC Data IncGlobalization and Health 2006, 2:6 http://www.globalizationandhealth.com/content/2/1/6
Page 4 of 14
(page number not for citation purposes)
tion interchange. Future research would benefit from bet-
ter surveillance of resistance, more comparable data
reporting, data on antibiotic utilization, and further meth-
odological advances in clinically- and policy-relevant
aggregation of "bug-drug" data.
Results
China
In 1988, the World Health Organization West Pacific
Regional Office set up two antimicrobial resistance sur-
veillance centers in Beijing and Shanghai. Meanwhile,
China's Ministry of Health also established the China
Nosocomial Infection Surveillance (CNIS) program,
which monitors hospital-acquired infections. Unfortu-
nately, most of the surveillance programs in China focus
on urban hospitals. We lack data on urban communities
and for the rural majority. Nevertheless, the available data
allows us to piece together a picture of the extent of anti-
microbial resistance in the most populous country in the
world.
To examine AMR development in China, we use annual
data from a seven-year (1994–2000) study by China's
National Center for Antimicrobial Resistance, which
reports resistance levels of ten most prevalent bacteria to a
common antibiotic, ciprofloxacin (Table 1) [25]. With
small sample sizes, the annual measured percentage of
isolates found to be resistant varies considerably; to
smooth the random variation attributable to small sam-
ple size, we use three-year running averages. Some bacte-
ria such as ECO and MRSA have high proportions (60–
80%) of resistant strains, whereas the prevalence of resist-
ant strains for others such as PMI is quite low. Almost all
but MSSA and PMI have shown considerable growth in
resistance over the study period, resulting in an average
annual growth rate of about 15%.
Another series of studies by the China Bacterial Resistance
Surveillance Study Group focused on resistance preva-
lence among different patient types, i.e. those with hospi-
tal-acquired infections (HAI) versus community-acquired
infections (CAI) [26,27]. We construct two measures to
compare HAI and CAI resistance prevalence. First, by
aggregating the seven bacteria, we get a measure γ indexed
on the nineteen drugs. γ is calculated by multiplying the
resistance rate of each bacterium by its isolation frequency
and proportion among HAI (or CAI) infections, and then
summing across bacteria. The measure is reported in the
last two columns of Table 2 and graphed in Figure 2. Sec-
ond, by aggregating the drugs, we obtain a measure
indexed on bacteria. However, because we lack data on
how often each drug is used, the best we can do is report
the simple average for all drugs (implicitly assuming each
drug is used with equal frequency). We name this measure
Mean Resistance, shown in the last row in Table 2 and
graphed in Figure 3.
Both measures reinforce the finding that infections
acquired in a hospital are often more drug resistant than
other (community-acquired) infections. For the seven
Table 1: Resistance prevalence of ten common bacteria to Ciprofloxacin in China, 1994–2000
unit: %
R a n k B a c t e r . 1 9 9 41 9 9 51 9 9 61 9 9 71 9 9 81 9 9 92 0 0 0 Average 
Resistance*
Average Growth 
Rate*
1 Escherichia coli (ECO) 53 49 60 61 60 63 62 59 3
2 Pseudomonas aeruginosa (PAE) 9 10 7 18 13 17 18 13 17
3 Klebsiella pneumoniae (KPN) 2 4 7 8 14 17 18 10 40
4 Staphylococci epidermidis (SEP) 22 33 34 35 41 40 46 36 9
5 Staphylococci aureus (SAU) MRS
A**
47 65 74 88 83 78 76 76 7
MSS
A**
81 8 1 05 82 0 1 4 11 8
6 E n t e r o c o c c u s  f a e c a l i s  ( E F A ) 2 53 42 83 43 24 54 5 34 9
7 Enterobacter cloacae (ECL) 12 9 13 14 22 31 30 18 26
8 A c i n e t o b a c t e r  b a u m a n n i i  ( A B A ) 7 7 1 92 02 33 13 7 20 29
9 C i t r o b a c t e r  f r e u n d i i  ( C F R ) 1 02 12 01 72 22 62 6 20 10
10 Proteus mirabilis (PMI) 8 2 13 2 5 14 12 71 0
Mea
n
28 15
Med
ian
20 10
* Based on three-year running averages.
** Staphylococci aureus (SAU) is further grouped as methicillin susceptible staphylococci aureus (MSSA) and methicillin resistant staphylococci 
aureus (MRSA).G
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Table 2: Resistance patterns of the seven most common bacteria for Hospital-acquired Infections (HAI) and Community-acquired Infections (CAI), China 2001
unit: %
Antibiotic(s) SAU (n = 176) SEP (n = 84) ECO (n = 308) ECL (n = 78) PAE (n = 232) KPN (n = 215) ABA (n = 191) γ
HAI 
(37)
CAI 
(139)
HAI 
(14)
CAI 
(70)
HAI 
(44)
CAI 
(264)
HAI 
(27)
CAI 
(51)
HAI 
(95)
CAI 
(137)
HAI 
(48)
CAI 
(167)
HAI 
(46)
CAI 
(145)
HAIγH CAIγC
Methicillin 89 30 43 27 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 11 5
Ampicillin 100 82 86 67 89 80 100 90 n/a n/a 54 66 n/a n/a 38 35
Amoxicillin 89 27 29 6 84 81 100 94 n/a n/a 90 95 48 50 38 31
Ceftizoxime 87 28 14 7 32 25 96 86 n/a n/a 33 26 96 92 24 16
Cefaclor 87 31 21 10 32 26 89 78 n/a n/a 33 25 65 57 23 15
Cefuroxime 89 29 22 4 32 25 74 47 n/a n/a 29 23 57 41 22 12
Cefprozil. 87 26 21 4 34 25 78 61 n/a n/a 33 23 94 86 24 15
Ceftazidime 92 37 50 13 5 7 59 28 11 14 21 4 30 15 19 8
Cefotaxime 84 28 21 6 0 7 44 26 41 26 4 5 28 16 15 8
Ceftriaxone 89 28 21 3 9 8 48 29 40 25 6 5 33 15 18 8
I m i p e n e m7 6 2 1 2 1 1200223012182
M e r o p e n e m 7 8 2 1 1 4 1200022012282
Ciprofloxacin 87 35 36 30 75 53 63 33 26 13 19 14 26 17 29 18
Ofloxacin 78 30 36 30 75 55 59 31 17 15 15 14 22 17 27 18
L e v o f l o x a c i n4 6 7 2 91 06 85 23 32 02 21 51 01 11 31 221 13
Sparfloxacin 89 39 50 40 75 56 63 33 43 31 25 16 15 14 32 21
M o x i f l o x a c i n5 2 1 4 3 6 44 32 21 84 32 7 4 8 1 31 517 12
G a t i f l o x a c i n3 011 443 6 2 57 62 3 1 76 61 5 1 4 13 7
Gentamicin 87 31 36 21 43 38 30 24 37 29 27 16 35 21 25 16
Mean 
Resistance
77 28 30 15 42 34 54 39 26 18 23 20 35 28Globalization and Health 2006, 2:6 http://www.globalizationandhealth.com/content/2/1/6
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bacteria, the mean resistance rate of HAI is on average 1.5
times that of CAI in China. For the nineteen drugs, the
aggregate measure of resistance for HAI, γH, is on average
1.9 times that for CAI, γC. This pattern is most extreme for
infections caused by SAU, where resistance of HAI is two-
to three- times that of CAI, depending on which measure
is used. (T-tests of the difference between two groups indi-
cate a p-value of less than 0.01 for the γ's and less than
0.09 for the mean resistance). Moreover, the prevalence of
drug resistance for both kinds of infections is quite high.
Mean resistance of HAI is 41% and that of CAI is 28%.
United States
Fairly comprehensive data on resistance trends in the U.S.
come from the National Nosocomial Infections Surveil-
lance System (NNIS) for hospital-based resistance, and
the U.S. Active Bacterial Core Surveillance (ABC) project,
which surveys a population of 16 million to 25 million
community residents in 9 states each year [28-30]. We use
data from an ABC program that surveys Streptococcus pneu-
moniae (SPN) from 1997 to 2002 to examine prevalence
and trends (Table 3). The average growth rate of resistance
for this bacterium was 8%, lower than the 15% number
for China. Interestingly, unlike the upward resistance
trend in China, SPN resistance declined in the last two
years of the study period in the US, following an initial
rise. Such data should not be interpreted to mean that
actual prevalence is permanently declining, since meas-
urement issues engender considerable year-to-year varia-
tion in the sample prevalence.
The US NNIS program provides data for inpatients and
outpatients. Further, among inpatients, the NNIS differ-
entiates between those in and not in the ICU. For almost
every bug-drug pair, resistance prevalence is highest
among ICU patients, followed by non-ICU inpatients,
with the lowest prevalence among outpatients (Table 4
and Figure 4). This pattern seems consistent with clinical
reality, since patients in ICUs are more likely to have a
weak immune system, either because of prolonged treat-
Hospital-acquired infections (HAI) are more resistant than community-acquired infections (CAI) to a wide range of antibiotics  in China Figure 2
Hospital-acquired infections (HAI) are more resistant than community-acquired infections (CAI) to a wide range of antibiotics 
in China.
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ment or their own compromised conditions; moreover,
many are catheterized, offering a conduit for bacteria.
Compared with China, the U.S. exhibits more moderate
differences in resistance prevalence among different
patients. The average prevalence of resistance for ICU,
other inpatients, and outpatients in the U.S. are 20%,
17% and 13%, respectively; in China, average resistance
for hospital-acquired infections is 41% and that for com-
munity-acquired infections is 28%.
Pooling all patients together (Table 5), we find the preva-
lence of resistance and its growth to be 17% and 7%
respectively, consistent with our previous observation that
the U.S. seems to have both lower resistance prevalence
and less dramatic increase in resistance than China does.
The Seven most common bacteria show higher resistance among hospital-acquired infections (HAI) than community-acquired  infections (CAI) in China Figure 3
The Seven most common bacteria show higher resistance among hospital-acquired infections (HAI) than community-acquired 
infections (CAI) in China.
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Table 3: Non-susceptibilities of Streptococcus pneumoniae (SPN) in U.S. communities, 1997–2002
Unit: %
Antibiotic 1997 1998 1999 2000 2001 2002 Average 
Resistance
Average 
Growth Rate
Penicillin 25 24 27 28 26 21 25 2
Cefotaxime 13 14 17 18 16 12 15 -1
Erythromycin 15 15 21 22 19 17 18 4
T M P / S u l f a 2 92 93 23 23 02 530 -3
Levofloxacin n/a 0.2 0.2 0.3 0.7 0.5 0.4 39
Vancomycin 000000 18 8Globalization and Health 2006, 2:6 http://www.globalizationandhealth.com/content/2/1/6
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Kuwait
There is considerably less detailed data on antibiotic
resistance for Kuwait than for China or the U.S. We gath-
ered data on antimicrobial resistance among isolates of
eight different bacterial diseases over the most recent five
years. The data is based on surveillance from a single large
Table 4: Resistance prevalence for selected drug-bug pairs by patient type, U.S. 1999–2002
unit: %
Pair Bacterium (resistant to) → 
drug
ICU patients non-ICU inpatients Outpatients
AP A E   → Ciprofloxacin/
ofloxacin
32 25 23
BP A E   → Levofloxacin 37 28 25
CP A E   → Imipenem 18 12 9
DP A E   → Ceftazidime 13 8 5
EP A E   → Piperacillin 16 11 6
FS A U   → Methicillin 47 38 23
G Enterococcus spp → 
Vancomycin
13 11 4
H ECO → C e f 3 * 110
I ECO → Quinolone** 5 4 2
J KPN → C e f 3 652
K Enterobacter spp → Cef3 26 21 10
L Enterobacter spp → 
Carbapenum
111
MC N S   → Methicillin 75 63 46
N Pneumococcus → Penicillin 18 17 17
O Pneumococcus → C e f 3 786
Mean 21 17 12
*Cef3 (3rd generation cephalosporin) = ceftazidime, cefotaxime or ceftriaxone;
**Quinolone = ciprofloxacin, ofloxacin or levofloxacin.
Table 5: Resistance prevalence of eight common bacteria, U.S. (all patients pooled), 1999–2002
unit: %
Bacterium Resistant to 
antibiotic(s)
1999 2000 2001 2002 Average 
Resistance
Average 
Growth Rate
PAE Ciprofloxacin
/ofloxacin
23 25 28 29 26 8
Levofloxacin 29 30 31 30 30 1
Imipenem 12 12 15 13 13 4
C e f t a z i d i m e 889994
Piperacillin 10 10 11 12 11 6
SAU (MRSA) Methicillin 32 35 38 39 36 7
Enterococcus 
spp
Vancomycin 11 8 10 10 10 -1
E C O C e f 3 111110
Q u i n o l o n e 234543 6
K P N C e f 3 444548
Enterobacter 
spp
Cef3 19 19 18 19 19 0
C a r b a p e n u m 111110
CNS Methicillin 60 61 62 63 62 2
Pneumococcu
s spp
Penicillin 14 16 19 19 17 11
C e f 3 587771 6
Mean: 17 7Globalization and Health 2006, 2:6 http://www.globalizationandhealth.com/content/2/1/6
Page 9 of 14
(page number not for citation purposes)
teaching hospital, Mubarak Al-Kabeer Hospital, which
serves a catchment area representing about 60% of
Kuwait's population. We report that data for the first time
here and in a companion paper [31] (see Tables 6, 7, 8,
9).The average resistance level for all surveyed bacteria
was about 27% from 1999 to 2003 (Table 10), higher
than the 17% for the U.S. and about the same as the 28%
China. As for the other two countries, resistance appears
to be growing in Kuwait.
Discussion: Comparing antibiotic resistance in 
China, the U.S. and Kuwait
In China, resistance rates exhibit a clear and rapid upward
trend. In the U.S., resistance currently appears to grow at
a more leisurely pace. Kuwait seems to be somewhere in
between. It is important to note that the pace of growth
may depend on the whether resistance to a particular anti-
biotic has reached a potential equilibrium. As shown in
the previous data, the 3% resistance growth rate of ECO
against Ciprofloxacin in China (Table 1), is considerably
lower than it is in the other two countries against similar
quinolone drugs (Table 5 and Table 10). This is probably
because ECO resistance may have virtually reached equi-
librium in China by the beginning of the study period;
hence it didn't grow much in subsequent years.
That resistance does not grow without bound highlights
the importance of comparing the current prevalence of
resistance in the three countries. After all, the prevalence
of resistance reflects the risk of a drug-resistant infection
for any given patient. A low rate of growth is small conso-
lation if patients already face a high baseline risk of a
acquiring an expensive, debilitating and even potentially
untreatable "superbug" infection.
The prevalence of resistance also substantially differs
across countries, although as noted previously, surveil-
lance data is far from ideal in capturing the true scope of
the problem. As shown in Table 11, using the data cur-
rently available, China has far higher prevalence of resist-
ICU patients have the highest resistance rates in selected drug-bug pairs, followed by non-ICU inpatients and outpatients, U.S.  1999–2002 Figure 4
ICU patients have the highest resistance rates in selected drug-bug pairs, followed by non-ICU inpatients and outpatients, U.S. 
1999–2002.Globalization and Health 2006, 2:6 http://www.globalizationandhealth.com/content/2/1/6
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ance for all the bacteria studied. For example, in China
resistance of SPN to one of the oldest antibiotics, erythro-
mycin, reaches 73%, while the figure for Kuwait is only
23%. A challenge for the U.S. is the exceptionally high
level of Vancomycin-Resistant Enterococcus spp (VRE). In
the U.S., 53% of Shigella spp are resistant to Trimetho-
prim/Sulfamethoxazole (TMP/SMX), in contrast to 0% in
both of the other countries. These examples suggest that
severity of resistance may be correlated with volume of
usage. Vancomycin is less affordable in both China and
Kuwait, presumably resulting in less usage in those coun-
tries.
Table 12 compares the three countries with Japan and Tai-
wan regarding prevalence of three important drug-resist-
ant bacteria: MRSA, penicillin resistant SPN (PRSP) and
vancomycin-resistant  Enterococcus  spp (VRE) [32-34].
Interestingly, each country has its own most problematic
resistance culprit. For China, MRSA is the biggest threat,
where resistance among hospital-acquired infections
reaches almost 90%, the highest among the five countries.
For the U.S., VRE is high. VRE growth in the U.S. can be
traced to the late 1980s and is probably among the highest
in the world. For Kuwait, PRSP is considerable. Both Tai-
wan and Japan are also troubled by at least one of these
three resistant bacteria.
Resistance correlations
How similar or different are resistance patterns in differ-
ent countries? Does transmission travel across national
Table 7: Resistance trend in isolates of Streptococcus pneumoniae over a 5-year period in Kuwait
Antibiotics Percentage (%) of resistant isolates in:
1999 (n = 78) 2000 (n = 61) 2001 (n = 73) 2002 (n = 66) 2003 (n = 90)
C e f o t a x i m e 00456
C e f t r i a x o n e 00354
C e f u r o x i m e 0089 4 1
Cephalexin 0 0 NT NT NT
Chloramphenicol 3 5 25 5 0
Erythromycin 16 20 23 26 30
I m i p e n e m 00000
Penicillin 32 38 46 52 54
T e i c o p l a n i n 00000
Vancomycin 00000
NT = not tested
Table 6: Resistance trend in isolates of Salmonella spp. over 5 years in Kuwait
Antibiotic Percentage (%) of resistant isolates in:
1999 (n = 216) 2000 (n = 215) 2001 (n = 129) 2002 (n = 167) 2003 (n = 165)
A m i k a c i n 00000
Ampicillin 6 12 7 25 26
Amoxicillin-
clavulanate
5 1 0720
C e f o t a x i m e 01010
C e f t r i a x o n e 01020
Cefuroxime 1 1 0 27 41
Cephalexin 2 10 37 57 50
Chloramphenicol 8 21 0 18 18
Ciprofloxacin 0 0 14 10 16
T M P / S M X 8 81 02 02 0
Gentamicin 6 1 0 42 42
I m i p e n e m 00000
M e r o p e n e m 00000
Piperacillin 6 13 13 23 25
Piperacillin/
tazobactam
00000
No ESBL-producing strain has been isolated so farGlobalization and Health 2006, 2:6 http://www.globalizationandhealth.com/content/2/1/6
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borders as humans do? If so, do countries' resistance pat-
terns converge? To begin to examine this issue, we con-
struct coefficients of resistance correlation among China,
U.S. and Kuwait. We rank resistance rates for 24 bug-drug
pairs and define perfect correlation as each bug-drug pair
displaying the same resistance rank. Perfect negative cor-
relation exists if the ranks in two countries go in precisely
the opposite order. Table 13 reports the correlation coeffi-
cient for each pair of countries. The statistic by definition
is bounded between -1 and 1, where -1 means perfect dis-
agreement while 1 means perfect agreement. Thus the big-
ger the statistic, the more correlated two countries'
resistance patterns are.
Of course, methods for aggregation and comparing pat-
terns of resistance across countries and over time should
be improved, and applied more fruitfully with better data
from increased local and global surveillance. But even this
preliminary analysis reveals some interesting patterns. For
example, resistance rates in China are much more strongly
correlated with those in Kuwait than those in the U.S. This
correlation pattern suggests that at least in the short run,
resistance in a country is more likely to be determined by
endogenous factors (such as strictness of practices for pre-
scribing drugs). In the long run, the frequency and magni-
tude of contacts among nations with different resistance
problems is likely to be critical. Because Kuwait and China
are relatively isolated countries, it is less surprising that
their antibiotic resistance problems show domestic char-
acters. However, as we expect them to be opening more to
the world, particularly China, the problem may worsen
when these countries can increasingly export and import
antibiotic resistance. China, the most populous country in
the world and an economy with the highest growth, is par-
ticularly likely to exacerbate the problem. As illustrated in
Figure 1, the number of Chinese departures to overseas
destinations has been growing at increasing rates in the
Table 8: Percentage of Enterococcus species resistant to often-tested antibiotics over 5 years in Kuwait
Antibiotic Percentage (%) of resistant isolates in:
1999 (n = 370) 2000 (n = 335) 2001 (n = 322) 2002 (n = 248) 2003 (n = 212)
Ampicillin 11320
Erythromycin 59 78 77 75 92
Gentamicin 26 36 61 52 98
Nitrofurantoin 2 2 2 36 86
Norfloxacin 36 47 47 NT NT
Penicillin 16 38 35 53 85
T e i c o p l a n i n 00010
Vancomycin 10020
NT = not tested
Table 9: Percentage of Staphylococcus aureus resistant to often-tested antibiotics over 5 years in Kuwait
Antibiotic Percentage (%) of resistant isolates in:
1999 (n = 648) 2000 (n = 595) 2001 (n = 484) 2002 (n = 420) 2003 (n = 286)
Ampicillin 96 100 98 96 98
Amoxicillin-clavulanic 
acid
63 32 72 22 9
C e p h a l e x i n 3 33 02 53 63 4
Ciprofloxacin 10 35 30 45 50
Clindamycin 18 24 20 20 27
Cloxacillin 23 24 9 22 17
Erythromycin 38 34 26 28 27
Fusidic acid NA 20 19 64 27
Gentamicin 25 21 16 24 27
Methicillin 23 24 9 22 17
Penicillin 95 95 99 96 99
T e i c o p l a n i n 00000
T M P / S M X 2 42 73 11 89 4
Vancomycin 00000Globalization and Health 2006, 2:6 http://www.globalizationandhealth.com/content/2/1/6
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past decade and continues to show upward momentum in
recent years.
No doubt, there are also complex interactions with levels
of economic well- being. Drugs become more affordable
as countries become richer, but they are likely to be given
out more carefully, particularly since concerns about
resistance also increase. The critical question for policy is
whether countries can control their own resistance prob-
lems, and also avoid importing the problem from abroad.
Conclusion
We have outlined the nature of the antimicrobial resist-
ance problem as an important health and cost issue for
three quite disparate nations, and by inference for a broad
swath of the world's population. Surprisingly, this issue
Table 10: Average Resistance Levels of Major Bacteria in Kuwait, 1999–2003
unit: %
ECO KPN PAE SPN Shigella 
spp.
Salmonella 
spp.
Enterococ
cus spp.
SAU Average 
Resistanc
e
Average 
Growth
Average 
Annual 
Resistance
13 8 5 31 45 65 37 8 27 17
Table 11: Resistance rates in China, U.S. and Kuwait, hospital surveillance data for 2001
From Tables 1,2,3,8 and 9; Unit: %
Bacterium(a) Antibiotic(s) Pair China U.S. Kuwait
SAU Methicillin A 37 38 9
SPN Erythromycin B 73 19 23
Cefotaxime C 0 16 4
Enterococcus spp Vancomycin D 4 10 0
ECO Ceftazidime E 9 1* 5
Cefotaxime F 18 1* 1
Ceftriaxone G 21 1* 1
Ciprofloxacin/
Ofloxacin
H5 632 6
PAE Ceftazidime I 17 9 27
Ciprofloxacin/
Ofloxacin
J2 7 2 8 3 1
KPN Ceftazidime K 9 4* 14
Cefotaxime L 17 4* 13
Ceftriaxone M 20 4* 13
Ciprofloxacin N 18 12**[27] 18
Salmonella spp Amoxicillin-
clavulanate
O1 04 7
Ceftriaxone P 5 1 0
Ciprofloxacin Q 0 0.4 10
TMP/SMX*** R 0 3 0
Gentamicin S 10 2 0
Shigella spp Amoxicillin-
clavulanate
T3 522 0
Ceftriaxone U 6 0 0
Ciprofloxacin V 6 0 0
TMP/SMX W 0 53 0
Gentamicin X 18 0.2 0
Average 17 7 9
* The original U.S. NNIS reported resistance rates to either one of the Cef3 drugs, i.e. ceftazidime, cefotaxime or ceftriaxone. We assume the same 
rates for each drug.
** Based on surveillance of ICU patients
*** TMP/SMX = Trimethoprim/SulfamethoxazoleGlobalization and Health 2006, 2:6 http://www.globalizationandhealth.com/content/2/1/6
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virtually never receives prominent attention at the
national or international level, despite its scope and
potentially devastating impact on global public health in
the coming decades.
We examined antimicrobial resistance data for China,
Kuwait, and the United States. In each country, we looked
at specific infectious agents and their resistance to partic-
ular antibiotics or other antimicrobials. Though an
upward trend of resistance is found broadly, the patterns
of correlation between countries' resistance rates suggest
predominantly independent profiles. But we would
expect greater convergence as globalization increases con-
tacts between different nations' populations, raising ques-
tions about how to coordinate an effective international
response [35].
Future research should develop better methods of data
aggregation, explore the patterns of drug resistance across
more countries, analyze the determinants of transmission
of drug resistance across national boundaries, and assess
how those determinants are progressing. Individuals eve-
rywhere would benefit if far greater attention were paid to
the problem of antimicrobial resistance.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Table 12: MRSA, PRSP & VRE in Selected Countries
Unit: %
MRSA (HAI only) PRSP VRE
China 89 (2001) 27 (2001) 0 (2001)
U.S. 16 (2001) 26 (2001) 0.3 (1989), 8 (1993), 12.8 (2001) in 
ICU
Kuwait 9 (2001) 46 (2001) 0 (2001)
Japan [33] 60–80% (1999) 11–40 (1999) n/a
Taiwan [34] n/a 69 (2000) 2 (2000)
Table 13: Ranks of resistance rates in China, U.S. and Kuwait, 2001(Rank correlations at bottom of table)
Bacterium(a) Antibiotic(s) China U.S. Kuwait
SAU Methicillin 32 1 1
SPN Erythromycin 144
Cefotaxime 21 5 14
Enterococcus spp Vancomycin 20 7 17
ECO Ceftazidime 15 17 13
Cefotaxime 81 8 1 5
Ceftriaxone 61 9 1 6
Ciprofloxacin/Ofloxacin 21 33
PAE Ceftazidime 11 8 2
Ciprofloxacin/Ofloxacin 531
KPN Ceftazidime 16 9 7
Cefotaxime 12 10 8
Ceftriaxone 71 19
Ciprofloxacin 966
Salmonella spp Amoxicillin-clavulanate 13 12 12
Ceftriaxone 19 20 18
Ciprofloxacin 22 21 10
TMP/SMX 23 14 19
Gentamicin 14 15 20
Shigella spp Amoxicillin-clavulanate 41 65
Ceftriaxone 17 23 21
Ciprofloxacin 18 24 22
TMP/SMX 24 1 23
Gentamicin 10 22 24
Correlation Coefficients CHN_US: 0.18 US_KW: 0.46 CHN_KW: 0.60Publish with BioMed Central    and   every 
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